Historical perspective on antipsychotic long-acting injections

British Journal of Psychiatry

Volumn 195, Issue SUPPL. 52, 2009, Pages

  Johnson, D A W ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPSYCHOTIC LONG ACTING INJECTION AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; LONG ACTING DRUG; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PHENOTHIAZINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; AUSTRIA; BLOOD PRESSURE; COMMUNITY CARE; DEPRESSION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG UTILIZATION; DYSLIPIDEMIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; GERMANY; HEALTH CARE QUALITY; HISTORY OF MEDICINE; HUMAN; HYPERGLYCEMIA; LONG TERM CARE; MAINTENANCE THERAPY; MENTAL DISEASE; MENTAL HEALTH SERVICE; PATIENT COMPLIANCE; POLYPHARMACY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SWEDEN; TARDIVE DYSKINESIA; TREATMENT DURATION; UNITED STATES; WEIGHT GAIN; DELAYED RELEASE FORMULATION; HISTORY; INJECTION; QUALITY OF LIFE;

ANTIPSYCHOTIC AGENTS; COMMUNITY NETWORKS; DELAYED-ACTION PREPARATIONS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; INJECTIONS; MEDICATION ADHERENCE; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 71249134477     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.195.52.s7     Document Type: Review

References (95)

1. Delay J, Deniker P. Trente-huit cas de psychoses traités par le cure prolongé et continue de 4560RP. Le Congrès des Al. et Neurol. de Langue Fr. Comptes Rendus du Congres Paris. Masson, 1952.
2. Scarpitti FR, Pasamanick BS. Medication in schizophrenia. Arch Gen Psychiatry 1964; 10: 143.
3. Prien RF, Cole JO, Belkin NF. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. Br J Psychiatry 1969; 115: 679-686
4. Denham J, Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr Scand 1971; 47: 420-430
5. Johnson DAW, Freeman HL. Long-acting tranquillisers. Practitioner 1972; 208: 395-400.
6. Gottfries GC, Green L. Fluphenthixol decanoate - in treatment of outpatients. Acta Psychiatr Scand Suppl 1974; 225: 15-24.
7. Hogarty GE, Goldberg SC, Schooler NR. Drug and sociotherapy in the aftercare of schizophrenic patients: one year relapse rates. Arch Gen Psychiatry 1973; 28: 54-64.
8. Hogarty GE, Goldberg SC, Schooler NR. Drug and sociotherapy in the aftercare of schizophrenic patients: two year relapse rates. Arch Gen Psychiatry 1974; 31: 603-608
9. Hogarty GE, Ulrich R, Goldberg SC. Sociotherapy and the prevention of relapse among schizophrenic patients. In Evaluation of Psychological Therapies (eds RL Spitzer, DF Klein): 285-293 Johns Hopkins University Press, 1976.
10. Hirsch SR, Gaind R, Rhode PD, Stevens BC, Wing JK. Outpatient maintenance of chronic schizophrenic patients with long acting phenothiazines. BMJ 1973; I: 633-637
11. Davis JM. Overview: maintenance therapy in schizophrenia. I. Schizophrenia. Am J Psychiatry 1975; 132: 1237-1245
12. Rifkin A, Quitkin F, Rabiner CJ. Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenia: relapse rate over one year. Arch Gen Psychiatry 1977; 34: 43-47 (Pubitemid 8023182)
13. Quitkin F, Rifkin A, Kane J, Ramos-Lorenzi JR, Klein DF. Long-acting oral drugs vs. injectable antipsychotic drugs in schizophrenia: a one year double-blind comparison in multi episode schizophrenia. Arch Gen Psychiatry 1978; 35: 889-892 (Pubitemid 9076802)
14. Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, et al. Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry 1980; 37: 16-24. (Pubitemid 10139118)
15. Tegeler J, Lehmann E. A follow-up study of schizophrenic outpatients treated with depot neuroleptics. Prog Neuropsychopharmacol 1981; 5: 79-90. (Pubitemid 11066665)
16. Wistedt B. A neuroleptic withdrawal study in chronic schizophrenic patients. Acta Psychiatr Scand 1981; 64: 65-84.
17. Kane JM, Rifkin A, Quitkin F, Nayak DV, Ramos-Lorenzi JR. Fluphenazine versus placebo in patients with remitted, acute first episodes of schizophrenia. Arch Gen Psychiatry 1982; 39: 70-73 (Pubitemid 12163378)
18. Johnson DAW. Depression: treatment compliance in general practice. Acta Psychiatr Scand Suppl 1983; 63 (suppl 290): 447-453
19. Johnson DAW. Observations on the use of long-acting depot neuroleptic injections in the maintenance treatment of schizophrenia. J Clin Psychiatry 1984, 45: 13-21.
20. Crow TJ, McMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148: 120-127 (Pubitemid 16158512)
21. Pietzcker A, Gaebel W, Kopcke W, Linden M, Muller P. A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Pharmacopsychiatry 1986; 19: 161-166 (Pubitemid 17171229)
22. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979; 36: 1283-1294
23. Kissling W (ed). Neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia: 50-52 Springer, 1991.
24. Johnson DAW. United Kingdom: neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed W Kissling): 45. Springer, 1991.
25. Dencker SJ. Sweden: neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed W Kissling): 24. Springer, 1991.
26. Fleischhacker WW, Meise U. Austria: the current status of maintenance treatment in schizophrenia. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed W Kissling): 13. Springer, 1991.
27. Cooper B, Shepherd M. Life change, stress and mental disorder: the ecological approach. In Modern Trends in Psychological Medicine. 2nd edn (ed JH Price): 102-130 Butterworth, 1970.
28. Pinel P. A Treatise on Insanity (trans. D Davis). History of Medicine Series No. 14. Hafner, 1962.
29. Kendal RE, Pighot P, von Cranach M. Diagnostic criteria of English, French and German psychiatrists. Psychol Med 1974; 4: 187-195
30. Kendal RE. The classification and phenomenology of schizophrenia: overview. In Contemporary Issues in Schizophrenia (ed A Kerr, P Snaith): 119-123 Gaskell, 1986.
31. Feigner JP, Robins E, Guze S, Woodruff RA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972; 26: 57-63.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM-III). APA, 1980.
33. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. BMJ 1971; 3: 599-604.
34. World Health Organization. The International Pilot Study of Schizophrenia, vol.1. WHO, 1974.
35. Mandelbrote BM. Schizophrenia: treatment and outcome. In Modern Trends in Psychological Medicine. 2nd edn (ed JH Price): 200-222 Butterworth, 1970.
36. Greenblatt M, York RH, Brown EL. From Custodial to Therapeutic Care in Mental Hospital. Russell Sage Foundation, 1955.
37. Bockhoven JS. Moral treatment in American society. J Nerv Ment Dis 1956; 124: 167.
38. Standt VM, Zubin J. A biometric evaluation of the somatotherapies in schizophrenia - a critical review. Psychol Bull 1957; 5: 171.
39. Moniz E. Tentatives Operatoires dans le Traitement de Certaines Psychoses. Masson, 1936.
40. Appel KE, Lhamon WT, Myers JM, Harvey WA. Long-term psychotherapy in psychiatric treatment. Res Publ Assoc Res Nerv Ment Dis 1953; 31: 21-41.
41. Wing JK, Brown GW. Social treatment of chronic schizophrenia: a comparative study of three mental hospitals. J Ment Sci 1961; 107: 847-861
42. Birley JLT, Brown GW. Crises and life changes preceding the onset or relapse of acute schizophrenia: clinical aspects. Br J Psychiatry 1970; 116: 327-333
43. Bebbington PE, Kuipers L. Social influences on schizophrenia. In Schizophrenia: The Major Issue (eds P Bebbington, P McGuffin): 202-225 Heinemann, 1988.
44. Greenblatt M. Drugs in combination with Other Therapies. Grune & Stratton, 1975.
45. Bebbington P, McGuffin P (eds). Schizophrenia: The Major Issues. Heinemann, 1988.
46. Taylor RDW, Huxley PJ, Johnson DAW. The role of social networks in the maintenance of schizophrenic patients. Br J Social Work 1984; 14: 129-140
47. Freeman HL (ed). Psychiatric Hospital Care. Baillière Tindall & Cassell, 1965.
48. Freeman HL, Johnson DAW. Progress to community care in an English city Pakistan Medical Forum 1970; 5: 25-34.
49. Davis JM, Schaffer CB, Kinard C, Chan C. Important issues in drug treatment of schizophrenia. Schizophr Bull 1980; 6: 70-87.
50. Kane JM. Treatment of schizophrenia. Schizophr Bull 1987; 13: 133-156
51. Barnes TRE, Hirsch SR. Neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed W Kissling). Springer, 1991.
52. Brown GW, Birley JLT, Wing JK. Influence of family life on the course of schizophrenic disorders: a replication. Br J Psychiatry 1972; 121: 241-258
53. Vaughn CE, Leff JP. The influence of family and social factors on the course of psychiatric illness. A comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976; 129: 125-137
54. Hogarty GE, Goldberg SC, Schooler NR. Drug and sociotherapy in the aftercare of schizophrenic patients. In Drugs in Combination with Other Therapies (ed M Greenblatt): 1-34. Grune & Stratton, 1975.
55. Cutting J. Outcome of schizophrenia: overview. In Contemporary Issues in Schizophrenia (eds A Kerr, P Snaith): 433-440 Gaskell, 1986.
56. Ley P, Spelman MS. Communicating with the Patient: 37-78. Staples Press, 1967.
57. Wilcox DRC, Gillan R, Hare EH. Do psychiatric patients take their drugs? BMJ 1965; 2: 790-792
58. Neve HK. Demonstration of Largactil in the urine. J Ment Sci 1958; 104: 488-491
59. Johnson DAW. Treatment of depression in general practice. BMJ 1973; 2: 18-20.
60. Johnson DAW. A study of the use of antidepressant medication in general practice. Br J Psychiatry 1974; 125: 186-192
61. Johnson DAW, Freeman HL. Drug defaulting by patients on long-acting phenothiazines. Psychol Med 1973; 3: 115-119
62. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatments of psychoses. Arch Gen Psychiatry 1988; 45: 79-81.
63. Hogarty GE, Ulrich RF, Mussare F, Austigueta N. Drug discontinuation among long term successfully maintained schizophrenic outpatients. Dis Nerv Syst 1976; 37: 494-500.
64. Wistedt B. A depot neuroleptic withdrawal study. Acta Psychiatr Scand 1981; 64: 65-84.
65. Marder SR, van Putten R, Mintz J, Lebell M, McKenzie J, May PRA. Low and conventional maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry 1987; 44: 518-522
66. Kissling W, Kane JM. Barnes TRE, Dencker ST, Fleischhacker WW, Goldstein MJ, et al. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed W Kissling). Springer, 1991.
67. Johnson DAW. The side-effects of fluphenazine decanoate. Br J Psychiatry 1973; 123: 519-522
68. Johnson DAW. Long term drug treatment of psychoses: observations on some current issues. Int Rev Psychiatry 1990; 2: 341-353
69. British Medical Association, Royal Pharmaceutical Society. British National Formulary. Antimuscarinic Drugs 4.9.2. BMJ Books/Pharmaceutical Press, 2008.
70. Johnson DA. Studies of depressive symptoms in schizophrenia. Br J Psychiatry 1981; 139: 89-101.
71. Johnson DA. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 1988; 152: 320-323 (Pubitemid 18077892)
72. Johnson DAW. Long term treatment of psychoses; observations on some current issues. Int Rev Psychiatry 1990; 2: 341-353
73. McGlashen TH, Carpenter WT. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 1976; 33: 231-239
74. McGlashen TH, Carpenter WT. An investigation of the postpsychotic depressive syndrome. Am J Psychiatry 1976; 133: 14-19
75. Knights A, Hirsch SR. Revealed depression and drug treatment for schizophrenia. Arch Gen Psychiatry 1981; 38: 806-811 (Pubitemid 11087241)
76. Mandel MR, Severe JB, Schooler NR. Development and prediction of postpsychotic depression in neuroleptic treated schizophrenia. Arch Gen Psychiatry 1982; 39: 197-203.
77. Roy A. Risk factor for suicide in psychiatric patients. Arch Gen Psychiatry 1982; 39: 1089-1095
78. van Putten T, May PRA. Akinetic depression in schizophrenia. Arch Gen Psychiatry 1978; 45, 1101-1107
79. Herz MI, Melville C. Relapse in schizophrenia. Am J Psychiatry 1980; 137: 801-805
80. Carpenter WR, Heinrich DW, Hanlon TE. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 1987; 144: 1466-1470
81. Brockington IF, Kendell RE, Kellett JM, Curry SH, Wainwright S. Trial of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br J Psychiatry 1978; 133: 162-168
82. Brockington IF, Kendell RE, Leff JP. Prognostic implications of six alternative definitions of schizophrenia. Arch Gen Psychiatry 1979; 36: 25-31.
83. Siris SG. Antidepressants in 'depressed' schizophrenics. In Depression in Schizophrenia (eds R Williams, JT Dalby): 215-232 Plenum, 1989.
84. Johnson DAW, Wright NK. Drug prescribing for schizophrenic out-patients on depot injections: repeat surveys over 18 years. Br J Psychiatry 1990; 156: 827-834
85. Johnson DAW, Rasmussen JGC. Professional attitudes in the UK towards neuroleptic maintenance therapy in schizophrenia. The problem of inadequate prophylaxis. Psychiatr Bull 1997; 21: 394-397
86. Kissling W. Ideal and reality of neuroleptic relapse prevention. Br J Psychiatry 1992; 161 (suppl 18): 133-139
87. Cassey DS. Relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58 (suppl 10): 55-62.
88. Correl CU, Leucht S, Kane JM. Lower risk for TD associated with secondary generation antipsychotics; a systematic review of 1 year studies. Am J Psychiatry 2004; 161: 414-425 (Pubitemid 38326094)
89. Bagnall AM, Jones L, Ginelly L, Lewis R, Glanville J, Gilbody S, et al. A systematic review of atypical antipsychotics in schizophrenia. Health Technol Assess 2008; 7: 13.
90. Jones PB, Barnes TRE, Davies L. Randomised controlled trial of the effect on quality of life of second vs first generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63: 1079-1087
91. Shirzadi AA, Ghaemi SN. Side-effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 2006; 14: 152-164
92. Blom-Cooper LJ, Hally H, Murphy E. The Falling Shadow: One Patient's Mental Healthcare 1978-1993. Report of the Committee of Inquiry into the Events Leading up to and Surrounding the Fatal Incident at the Edith Morgan Centre, Torbay, on 1 September 1993. Duckworth, 1995.
93. Thornicroft G. National Service Framework for Mental Health. Psychiatr Bull 2000; 24: 203-206 (Pubitemid 30337875)
94. Patel M, Nikolaou V, David AS. Eliciting psychiatrists' beliefs about side effects of typical and atypical antipsychotic drugs. Int J Psychiatry Clin Pract 2003; 7: 117-120 (Pubitemid 36917075)
95. Patel MX, David AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treat 2005; 11: 203-211